Group 1 - The core viewpoint of the articles highlights the performance and valuation of Canan Technology Co., Ltd. in the medical device industry, noting its current stock price and market capitalization [1][2] - As of July 24, the stock price of Canan Technology closed at 23.27 yuan, reflecting a 3.51% increase, with a rolling PE ratio of 79.62, marking a new low in 84 days, and a total market value of 2.845 billion yuan [1] - The average PE ratio for the medical device industry is 54.55, with a median of 37.54, positioning Canan Technology at the 100th rank within the industry [1][2] Group 2 - In terms of capital flow, on July 24, Canan Technology experienced a net inflow of 10.8779 million yuan, with a total inflow of 1.5107 million yuan over the past five days [1] - The company specializes in the research, production, and sales of injection puncture instruments and laboratory consumables, recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1] - The latest financial results for the first quarter of 2025 show that Canan Technology achieved an operating income of 72.7093 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34%, with a gross profit margin of 31.15% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Canar Medical Co., which has a current PE ratio of 77.63, marking a new low in 78 days, with a total market capitalization of 2.774 billion yuan [1][2] - Canar Medical's main business includes the research, production, and sales of injection and puncture instruments and laboratory consumables, and it has been recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1] - The latest quarterly report for Q1 2025 shows that Canar Medical achieved operating revenue of 72.7093 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34% year-on-year, with a gross profit margin of 31.15% [1] Group 2 - In terms of industry comparison, the average PE ratio for the medical device industry is 52.71, with a median of 37.14, positioning Canar Medical at the 98th rank within the industry [1][2] - The number of shareholders for Canar Medical has increased to 7,596, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Canan Technology Co., Ltd., particularly its high PE ratio compared to industry averages [1][2] - As of July 16, Canan's closing price was 22.24 yuan, with a rolling PE ratio of 76.09 times, significantly higher than the industry average of 51.87 times and the median of 37.48 times [1][2] - The company has a total market capitalization of 2.719 billion yuan, ranking 99th in the medical device industry based on PE ratio [1][2] Group 2 - In terms of capital flow, Canan experienced a net outflow of 1.283 million yuan on July 16, with a total outflow of 3.9893 million yuan over the past five days [1] - The company's main business includes the research, production, and sales of injection and puncture instruments and laboratory consumables, and it has been recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1] - The latest financial results for Q1 2025 show that Canan achieved operating revenue of 72.7093 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34%, with a gross profit margin of 31.15% [1]

Company Overview - Company name is采纳科技股份有限公司, primarily engaged in the research, production, and sales of injection puncture instruments and laboratory consumables [1] - Main products include medical devices, animal instruments, and laboratory consumables [1] - Recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province and a provincial-level leading enterprise in agricultural industrialization [1] Financial Performance - As of Q1 2025, the company reported revenue of 72.71 million yuan, a year-on-year decrease of 34.28% [1] - Net profit for the same period was 7.68 million yuan, down 69.34% year-on-year [1] - Gross profit margin stood at 31.15% [1] Market Position - The company's closing stock price was 21.21 yuan, down 1.49%, with a rolling PE ratio of 72.57 times [1] - Total market capitalization is 2.593 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 51.05 times and a median of 36.62 times, the company ranks 99th [1][2] Institutional Holdings - As of Q1 2025, five institutions held shares in the company, with a total holding of 25.89 million shares valued at 57.1 million yuan [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Canan Co., which operates in the medical device industry, showing a significant decline in revenue and profit in the latest quarterly report [1][2] - As of June 19, Canan Co. closed at 19.96 yuan, down 2.59%, with a rolling PE ratio of 68.29, significantly higher than the industry average of 48.08 and the median of 36.05, ranking 99th in the industry [1][2] - The total market capitalization of Canan Co. is 2.44 billion yuan, with 5 institutions holding a total of 25.89 million shares valued at 571 million yuan [1] Group 2 - In the first quarter of 2025, Canan Co. reported revenue of 72.71 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.68 million yuan, down 69.34%, with a gross profit margin of 31.15% [1] - The company specializes in the research, production, and sales of injection and puncture instruments and laboratory consumables, recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1]

采纳科技股份有限公司的主营业务是注射穿刺器械及实验室耗材的研发、生产和销售。公司的主要产品 是医疗器械、动物器械、实验室耗材等。公司被认定为江苏省专精特新中小企业、农业产业化省级龙头 企业。 最新一期业绩显示，2025年一季报，公司实现营业收入7270.93万元，同比-34.28%；净利润768.02万 元，同比-69.34%，销售毛利率31.15%。 5月22日，采纳股份今日收盘20.55元，下跌1.82%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到70.31倍，总市值25.12亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均48.71倍，行业中值35.37倍，采纳股份排 名第100位。 截至2025年一季报，共有5家机构持仓采纳股份，其中其他4家、保险1家，合计持股数2588.95万股，持 股市值5.71亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)100采纳股份70.3147.321.3825.12亿行业平均 48.7146.924.57105.44亿行业中值35.3737.132.4047.42亿1天益医疗-1727.26-2958.601.8422.0 ...

Group 1 - The closing price of Canan Co., Ltd. on May 14 was 19.99 yuan, down 2.06%, with a rolling PE ratio of 68.40 times and a total market value of 2.444 billion yuan [1] - In the medical device industry, the average PE ratio is 49.84 times, and the median is 36.65 times, placing Canan Co., Ltd. at the 98th position in the industry ranking [1] - The main business of Canan Co., Ltd. includes the research, production, and sales of injection puncture instruments and laboratory consumables, with key products being medical devices, animal instruments, and laboratory consumables [1] Group 2 - For the first quarter of 2025, Canan Co., Ltd. reported operating revenue of 72.7093 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34% year-on-year, with a gross profit margin of 31.15% [1] - The company has been recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province and a provincial-level leading enterprise in agricultural industrialization [1]

证券代码：301122 证券简称：采纳股份 采纳科技股份有限公司 投资者关系活动记录表 编号：2025-001 投资者关系活 动类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐其他（请文字说明其他活动内容） 参与单位名称 及人员姓名 线上参与公司2024年度业绩说明会的投资者 时间 2025年04月30日 15:00-16:00 地点 价值在线（https://www.ir-online.cn/）网络互动 上市公司接待 人员姓名 董事长兼总经理：陆军先生 董事会秘书：陆维炜先生 财务负责人：查凌云女士 独立董事：刘斌先生 保荐代表人：钟祝可先生 投资者关系活 动主要内容介 绍 1.根据2024年第三季度报告，采纳股份主营收入同比下降16.14%，归 母净利润下滑38.02%，扣非净利润降幅更高达44.09%，请问2025年有什么 措施保持财务健康度与盈利能力的持续性？ 答:尊敬的投资者，您好！公司2024年度归母净利润同比下降，主要系 本期受美国FDA进口警示影响，部分产品销售不及预期，同时针对受到进口 警示影响的部分存货、应收款项等项目计提了相应的减值准备 ...